EPICS Conference Coverage ESMO 2020 Breast Cancer Highlights
Practice changes and horizon openings from ESMO 2020 and beyond: triple-negative breast cancer, HR+/HER2+ early and metastatic breast cancer.
FACULTY CO-CHAIR
Joyce A. O’Shaughnessy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US
FACULTY CO-CHAIR
Nadia Harbeck, MD, PhD
Ludwig-Maximilians-University of Munich – Breast Center, Germany
Faculty Members
Adam Brufsky, MD, PhD
UPMC Hillman Cancer Center, Pittsburgh, PA, US
David Cameron, MD
Edinburgh University, Scotland
Pierfranco Conte, MD
University of Padua, Italy
Joseph Gligorov, MD, PhD
Tenon Hospital, Paris, France
Antonio Llombart-Cussac, MD, PhD
Hospital Arnau de Vilanova, Universidad Catolica Valencia, Spain
Andreas Schneeweiss, MD
Heidelberg University Hospital, Germany
PROGRAM OVERVIEW
Aptitude Health conducted a series of online breast cancer expert forums focused on current and emerging approaches in triple-negative breast cancer, and on advances in HR+/HER2+ early stage and metastatic breast cancer. Life science partners had the ability to silently observe these important and timely online faculty discussions and received a comprehensive summary report including customized content specific to their products and areas of expertise.
2 VIRTUAL INTERACTIVE SESSIONS
Day 1 | EPICS Advisory Board Session TNBC and HR+ BC
The faculty, consisting of top breast cancer experts, will share their views via a 3-hour interactive virtual discussion on the newest clinical data, current treatment approaches, and their vision for how the landscape is likely to change in the future. Each clinical data presentation will be followed by a moderated discussion. During this first EPICS session, all stages of triple-negative breast cancer will be discussed.
Day 2 | EPICS Advisory Board Session HR+/HER2+
The clinical expert faculty will share their views during a 3-hour virtual discussion on the newest clinical data and treatment evolutions specific to HR+/HER2+ breast cancer.
